Authors
Parakkal Deepak, Wooseob Kim, Michael A Paley, Monica Yang, Alexander B Carvidi, Emanuel G Demissie, Alia A El-Qunni, Alem Haile, Katherine Huang, Baylee Kinnett, Mariel J Liebeskind, Zhuoming Liu, Lily E McMorrow, Diana Paez, Niti Pawar, Dana C Perantie, Rebecca E Schriefer, Shannon E Sides, Mahima Thapa, Maté Gergely, Suha Abushamma, Sewuese Akuse, Michael Klebert, Lynne Mitchell, Darren Nix, Jonathan Graf, Kimberly E Taylor, Salim Chahin, Matthew A Ciorba, Patricia Katz, Mehrdad Matloubian, Jane A O’Halloran, Rachel M Presti, Gregory F Wu, Sean PJ Whelan, William J Buchser, Lianne S Gensler, Mary C Nakamura, Ali H Ellebedy, Alfred HJ Kim
Publication date
2021/11
Journal
Annals of internal medicine
Volume
174
Issue
11
Pages
1572-1585
Publisher
American College of Physicians
Description
Background
Patients with chronic inflammatory disease (CID) treated with immunosuppressive medications have increased risk for severe COVID-19. Although mRNA-based SARS-CoV-2 vaccination provides protection in immunocompetent persons, immunogenicity in immunosuppressed patients with CID is unclear.
Objective
To determine the immunogenicity of mRNA-based SARS-CoV-2 vaccines in patients with CID.
Design
Prospective observational cohort study.
Setting
Two U.S. CID referral centers.
Participants
Volunteer sample of adults with confirmed CID eligible for early COVID-19 vaccination, including hospital employees of any age and patients older than 65 years. Immunocompetent participants were recruited separately from hospital employees. All participants …
Total citations
Scholar articles
P Deepak, W Kim, MA Paley, M Yang, AB Carvidi… - Annals of internal medicine, 2021